What Options Are There?

There may be options to help you afford your Genentech medicine, no matter what type of health insurance you have.

Referrals to Independent Co-pay Assistance Foundations

If you need help with your co-pay for your Genentech medicine, Genentech Rheumatology Access Solutions can refer you to an independent co-pay assistance foundation.

An independent co-pay assistance foundation is a charitable organization that gives financial assistance for medicines.

Call Genentech Rheumatology Access Solutions at (866) 681-3261 for a referral.

If you would like to contact a foundation directly, you can use the information below:

No funds are available at this time.

Please call Genentech Rheumatology Access Solutions at (866) 681-3261. We may be able to help.

No funds are available at this time.

Please call Genentech Rheumatology Access Solutions at (866) 681-3261. We may be able to help.

 

Independent co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only can refer you to a foundation that supports your disease state. This information is provided as a resource for you. We do not endorse or show financial preference for any particular foundation. The foundations in this list are not the only ones that might be able to help you.

Referrals to the Genentech® Access to Care Foundation

The Genentech Access to Care Foundation, or GATCF, can help you receive your Genentech medicine free of charge, if you qualify.

GATCF helps people who are:

  • Uninsured—People who do not have insurance
  • Rendered uninsured—People whose health insurance does not cover their Genentech medicine
  • Underinsured—People who have health insurance (including commercial or government insurance plans), but pay more than a certain amount for their medicines each year

Other eligibility criteria must be met to qualify for free medicine from GATCF. You might qualify if you meet the requirements below.

  • Do you have health insurance?

  • Is your yearly household income less than $100,000?

  • Is your yearly household income less than $150,000?

  • Do you spend 5% or more of your yearly household income on the out-of-pocket costs for your Genentech medicine?

You Might Qualify for Free Medicine From GATCF

To apply for GATCF, you’ll need to complete the PAN form and your doctor’s office will need to complete the SMN form.

Be sure to fill out Sections 5 and 6 on the PAN form.

Download the SMN and PAN

Other Options May Be Available

You do not appear to qualify for free medicine from GATCF. However, other patient assistance options may be available to help you.

Find Out Which Option May Be Right for You

You can also call Genentech Rheumatology Access Solutions at (866) 681-3261 and speak with one of our Specialists.

You’ll have to fill out Sections 5 and 6 of the PAN form to apply for GATCF.

If you have health insurance, you must have already tried other types of patient assistance to qualify for free Genentech medicine from GATCF. This includes the ACTEMRA Co-pay Card Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance, you must meet different financial criteria.

Referrals to the ACTEMRA Co-pay Card Program

Genentech Rheumatology Access Solutions can refer you to the ACTEMRA Co-pay Card Program. It can help you with the out-of-pocket costs of your Genentech medicine, if you’re eligible.

The ACTEMRA Co-pay Card Program helps patients with commercial health insurance. This might be a plan you get through your employer or one you purchased through a Health Insurance Marketplace like HealthCare.gov. To qualify, you must also meet other criteria.

In order to be eligible for the ACTEMRA Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit RACopay.com for the full list of terms and conditions.

How to Work With Genentech Rheumatology Access Solutions

 

Step 1

Enroll in Genentech Rheumatology Access Solutions.

How do I enroll?

Step 2

We work with you, your doctor’s office, your health insurance plan and your specialty pharmacy. We might contact you for more information.

What will we find out?

Step 3

We refer you to patient assistance options.

What options are there?

PAN=Patient Authorization and Notice of Request for Transmission of Health Information to Genentech Access Solutions and Genentech® Access to Care Foundation.

SMN=Statement of Medical Necessity.

Important Safety Information & Indication

What it Treats

ACTEMRA® (tocilizumab) is a prescription medicine used to treat:

  • Adults with moderately to severely active rheumatoid arthritis, or RA. ACTEMRA is used after at least one other medicine called a Disease Modifying Anti-Rheumatic Drug (DMARD) has been used and did not work well.
  • Adults with giant cell arteritis (GCA).
  • People with active polyarticular juvenile idiopathic arthritis (PJIA) age 2 years and above.
  • People with active systemic juvenile idiopathic arthritis (SJIA) age 2 years and above.
  • People who experience severe or life-threatening CRS following chimeric antigen receptor T cell treatment age 2 years and above.

ACTEMRA is not approved for subcutaneous use in people with SJIA or CRS.

It is not known if ACTEMRA is safe and effective in children with PJIA or SJIA under 2 years of age, in children with CRS under 2 years of age, or in children with conditions other than PJIA, SJIA or CRS.

Important Safety Information

ACTEMRA can cause serious side effects. ACTEMRA changes the way a patient’s immune system works. This can make a patient more likely to get infections or make any current infection worse. Some patients have serious infections while taking ACTEMRA, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some patients taking ACTEMRA have died from these infections.

ACTEMRA can cause other serious side effects. These include:

  • Stomach tears
  • Changes in blood test results, including low neutrophil (white blood cells) and platelet (platelets help the blood to clot) counts, and increases in certain liver function test levels and blood cholesterol levels
  • An increased risk of certain cancers by changing the way a patient’s immune system works
  • Hepatitis b infection in people who carry the virus in their blood
  • Serious allergic reactions, including death. These may happen with ACTEMRA infusions or injections, even if they did not occur with an earlier infusion or injection. If a patient has had hives, a rash, or experienced flushing after injecting, the patient should tell their doctor or nurse before their next injection
  • Nervous system problems

ACTEMRA affects the immune system and may increase a patient’s risk of certain cancers.

Most common side effects in patients treated with ACTEMRA:

Patients must tell their doctor if they have these or any other side effect that bothers them or does not go away:

  • Upper respiratory tract infections (like common cold and sinus infections)
  • Headache
  • Increased blood pressure (also called hypertension)
  • Injection site reactions (for subcutaneous use only)

ACTEMRA & pregnancy:

Patients must tell their doctor if they are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. The patient and their doctor should decide if the patient will take ACTEMRA or breast-feed. Patients should not do both. If a patient is pregnant and taking ACTEMRA, they must join the pregnancy registry. To learn more, patients should call 1-877-311-8972 or talk to their doctor to register.

Patients must tell their doctor right away if they are experiencing any side effects.

Report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Call Genentech at 1-888-835-2555.

Please see the full Prescribing Information, including BOXED WARNING and Medication Guide, for additional Important Safety Information.